Influence of vein injury in different methods of chemotherapy in mice
Tóm tắt
To explore the effects of cisplatin chemotherapy via the vein and the abdominal cavity on the functions of endothelial cells of mice with non-small cell lung cancer. 75 mice were divided equally into a untreated group, a group treated with chemotherapy (cisplatin: 2 mg/kg, 0.5 mL) via an intravenousmethod and a group treated with chemotherapy (cisplatin: 2 mg/kg, 0.5 mL) via an intraperitoneal method; changes in the morphology and ultrastructure of vein endothelial cells were observed. The injury of the intima of the intravenous chemotherapy group was similar to that of the intraperitoneal chemotherapy group. The injury of vein endothelial cells is not significantly related to the choice of intravenous injection or intraperitoneal injection.
Tài liệu tham khảo
Kubota T, Andoh K, Sedakata H, et al. Tissue factor released from leukemic cells. Thromb Haemost 1991; 65: 59–63.
Gordon SG, Benson B. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 1989; 56: 431–440.
Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78: 133–136.
AL-Mondhiry H. Betathromboglobulin and platelet factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy. Am J Hematol 1983; 14: 105–165.
Wehmeier A, Tschope D, Esser J, et al. Circulationg activated platelets in myeloproliferative disorders. Thromb Res 1991; 61: 271–278.
Grignani G, Paccdhiarini L, Pagliarino M. The possible role of bloos platelets in tumour growth and dissemination. Haematologica 1986; 71: 245–255.
Kwaan HC, Keet HN. Fibrinolysis and cancer. Semin Thromb Hemost 1990; 16: 230–235.
Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369–377.
Ross R. Atherosclerosis: current understanding of mechanisms and future strategies in therapy. Transplant Proc 1993; 25: 2041–2043.
Clancy RM. Circulating endothelial cells and vascular jury in systemic lupus erythematosus. Curr Rheumatol Rep 2000; 2: 39–43.
Laight DW, Carrier MJ, Anggard EE. Endohtelial cell dysfunction and pathogenesis of diabetic macroangiopahty. Diabetes Metab Res Rev 1999; 15: 274–282.
Grignani G and Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967–972.
Contrino J, Hair G, Kreutzer DL, et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209–215.
Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. Blood 2003; 101: 2637–2645.
Andrews RK, Bemdt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114: 447–453.
Cruz MA, Chen J, Whitelock JL, et al. The platelet glycoprotein Ib Von Willebrand factor interaction activates the collagen receptor a2b1 to bind collagen: activation dependent conformation change of the a2-I domain. Blood 2005; 105: 1986–1991.
Makin AJ, Blann AD, Chung NA, et al. Asesssment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with Von Willebrand factor and tissue factor. Eur Heart J 2004; 25: 371–376.
Lee KW, Lip GY, Tayebjee M, et al. Circulating endothelial cells, Von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526–532.
Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with non small cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005; 103: 994–999.
Togna GI, Togna AR, Franconi M, et al. Cisplatin triggers platelet activation. Thromb Res 2000; 99: 503–509.
Licciardello JT, Moake JL, Rudy CK, et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985; 42: 296–300.
Jacobson G, Kamath R, Smith B, et al. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol 2005; 96: 470–474.